95 related articles for article (PubMed ID: 23339090)
1. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.
Cetintas VB; Tetik A; Cok G; Kucukaslan AS; Kosova B; Gunduz C; Veral A; Eroglu Z
Cell Biol Int; 2013 Jan; 37(1):78-86. PubMed ID: 23339090
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.
Cetintas VB; Kucukaslan AS; Kosova B; Tetik A; Selvi N; Cok G; Gunduz C; Eroglu Z
Cell Biol Int; 2012 Mar; 36(3):261-5. PubMed ID: 22397496
[TBL] [Abstract][Full Text] [Related]
3. Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells.
Tezcanli Kaymaz B; Bozok Cetintas V; Eroglu Z; Kosova B
J BUON; 2014; 19(1):145-52. PubMed ID: 24659656
[TBL] [Abstract][Full Text] [Related]
4. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
5. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
6. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V
Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297
[TBL] [Abstract][Full Text] [Related]
8. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
Zhang W; Wan M; Ma L; Liu X; He J
Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
11. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
Zang YS; Zhong YF; Fang Z; Li B; An J
Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
[TBL] [Abstract][Full Text] [Related]
12. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
[TBL] [Abstract][Full Text] [Related]
13. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
Shang XB; Yu ZT; Tang P; Zhang XZ
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
[TBL] [Abstract][Full Text] [Related]
14. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
15. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
17. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
18. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP).
Wang Q; Zhong M; Liu W; Li J; Huang J; Zheng L
Exp Lung Res; 2011 Sep; 37(7):427-34. PubMed ID: 21787234
[TBL] [Abstract][Full Text] [Related]
19. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment.
Hsieh JL; Lu CS; Huang CL; Shieh GS; Su BH; Su YC; Lee CH; Chang MY; Wu CL; Shiau AL
Cancer Lett; 2012 Aug; 321(1):36-44. PubMed ID: 22450752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]